Moderna wins on expanded pact with plasmid DNA supplier
By Dhirendra Tripathi
Invest – Moderna (NASDAQ 🙂 rose more than 2% on Monday as the company sought to strengthen its global presence as a key supplier of Covid-19 vaccines by expanding its deal with Aldevron, its existing supplier of plasmid DNA.
Moderna and Pfizer (NYSE 🙂 – BioNTech’s (NASDAQ 🙂 Covid-19 vaccines, based on mRNA technology, have been shown to be the most effective at developing antibodies against the coronavirus.
Aldevron’s DNA production already takes place at its 70,000 square foot factory in Fargo, North Dakota. Construction and validation of an additional 189,000 square foot expansion has been completed, allowing additional manufacturing capacity.
The company, founded in 1998, will supply plasmid DNA that will serve as a genetic model to generate the Covid-19 mRNA vaccine and other research programs in the Moderna pipeline.
Aldevron supplies essential nucleic acids and proteins used in gene and cell therapy. It is a leading supplier of high quality plasmid DNA, mRNA and recombinant proteins required for vaccines, gene and cell therapy, gene editing and diagnostic applications.
Moderna plans to deliver 800 million to 1 billion doses of its Covid-19 vaccine in 2021, with an additional 2 billion doses to be provided in 2021, with production coming from its own facilities and those of its partners.